Rege Nephro Acquires Tamibarotene Assets from Syros Pharmaceuticals to Enhance Kidney Disease Therapies
- Rege Nephro acquired Tamibarotene assets from Syros Pharmaceuticals to enhance kidney disease therapeutics development.
- The acquisition includes critical safety data, manufacturing contracts, and the active pharmaceutical ingredient for Tamibarotene.
- Rege Nephro is advancing its Phase 2 trial for Tamibarotene, showing promising early efficacy and safety results.
Rege Nephro Expands Clinical Horizons with Acquisition of Tamibarotene Assets from Syros Pharmaceuticals
Rege Nephro Co., Ltd., a clinical-stage biotechnology company based in Kyoto, Japan, strengthens its portfolio by acquiring comprehensive clinical and non-clinical assets related to Tamibarotene from Syros Pharmaceuticals. This strategic acquisition, finalized on February 26, 2025, provides Rege Nephro with critical data and resources that will enhance its capabilities in developing new therapeutics for kidney diseases. Tamibarotene (RN-014), a retinoic acid receptor agonist, is currently under investigation in a Phase 2 clinical trial for autosomal dominant polycystic kidney disease (ADPKD) in Japan, with aspirations to expand its clinical trials to the United States upon demonstrating safety and efficacy.
The acquisition includes valuable components such as human safety studies necessary for a New Drug Application (NDA), contracts with a contract manufacturing organization (CMO), and the active pharmaceutical ingredient (API) along with finished drug products for Tamibarotene. This move is not just a significant addition to Rege Nephro’s arsenal but also positions them strategically in the competitive landscape of renal therapeutics. The company aims to leverage these assets to streamline its clinical trial processes, thereby accelerating the potential introduction of new therapies for patients suffering from kidney conditions.
Rege Nephro's focus on innovative therapeutics is highlighted by its collaboration with Kyoto University’s Center for iPS Cell Research and Application (CiRA). With the initiation of the Phase 2 trial for RN-014 in December 2023, the company reports encouraging preliminary results, indicating no major safety concerns alongside promising early efficacy signals. Such developments are vital, as they not only enhance Rege Nephro's research capabilities but also contribute to the growing field of regenerative medicine aimed at treating complex diseases that have historically posed significant challenges.
In related news, Rege Nephro's commitment to advancing renal therapies is further exemplified by its ongoing research initiatives aimed at a broader spectrum of kidney, liver, and pancreatic diseases. As the company continues to explore new treatment avenues, the acquisition of Tamibarotene-related assets signifies a pivotal step towards fulfilling its mission of delivering innovative solutions to patients in need. For more information on their efforts, visit www.regenephro.co.jp/en.